Bhanwar Singh Choudhary

Employment

• Swami Rama Himalayan University Assistant Professor
  2026 - Present
• Universityof CapeTown Postdoctoral Research Fellow
  2024 - 2025
• Ganpat University Assistant Professor
  2021 - 2022
• Sardar Bhagwan Singh Post Graduate Institute of Biomedical Science and Research Assistant Professor
  2012 - 2014

Education

• Central University of Rajasthan PhD Pharmacy
  2015 - 2022
• Narsee Monjee Institute of Management Studies University M. Pharmacy (Pharmaceutical Chemistry)
  2009 - 2011
• Sardar Bhagwan Singh Post Graduate Institute of Biomedical Science and Research B. Pharmacy
  2005 - 2009

Projects & Funding

Projects & funding information is unavailable.

Publications (26)

• Exploring 2‐Thioxo‐1,2,3,4‐tetrahydropyrimidines as Dual Acting GSK‐3β/Aβ Aggregation Inhibitors: Implications for Alzheimer's Disease Treatment
  Drug Development Research 2025 DOI: 10.1002/ddr.70112
  +Save
• Dual Inhibitors Targeting G9a and GSK-3β: Translational Perspectives on Alzheimer’s Disease Treatment
  Biorxiv 2025 DOI: 10.1101/2025.10.24.684310
  +Save
• First-in-Class SAM-Competitive G9a Inhibitor FLAV-27 as a Disease-Modifying Therapy for Alzheimer’s Disease
  Research Square 2025 DOI: 10.21203/rs.3.rs-6940373/v1
  +Save
• G9a an Epigenetic Therapeutic Strategy for Neurodegenerative Conditions: From Target Discovery to Clinical Trials
  Medicinal Research Reviews 2025 DOI: 10.1002/med.22096
  +Save
• First-in-Class SAM-Competitive G9a Inhibitor FLAV-27 as a Disease-Modifying Therapy for Alzheimer’s Disease
  Molecular Therapy 2025 DOI: 10.1016/j.ymthe.2025.12.038
  +Save
• Design, synthesis, and biological evaluation of tetrahydropyrimidine analogue as GSK-3β/Aβ aggregation inhibitor and anti-Alzheimer’s agent
  Bioorganic Chemistry 2024 DOI: 10.1016/j.bioorg.2024.107811
  +Save
• G9a Inhibition Promotes Neuroprotection through GMFB Regulation in Alzheimer’s Disease
  Aging and disease 2024 DOI: 10.14336/ad.2023.0424-2
  +Save
• Dual Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors: The Quest for a Disease-Modifying Treatment for Alzheimer’s Disease
  Deciphering Drug Targets for Alzheimers Disease 2023 DOI: 10.1007/978-981-99-2657-2_4
  +Save
• Dual Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors: The Quest for a Disease-Modifying Treatment for Alzheimer’s Disease
  Deciphering Drug Targets for Alzheimer’s Disease 2023 DOI: 10.1007/978-981-99-2657-2_4
  +Save
• Structure-based virtual screening, biological assessment, and MD simulation studies of novel CNS compatible GSK-3β inhibitors as potential Alzheimer’s disease therapeutics
  Research Square 2022 DOI: 10.21203/rs.3.rs-1309750/v1
  +Save